Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

09/07/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.27%, closing at 52487.41 points; the Nasdaq Composite rose by 1.3%, closing at 26206.89 points; the S&P 500 Index rose by 0.81%, closing at 7543.64 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Julong Holding Limited Class A: Overnight gain 318.0%, Surges Amid Small-Cap Appeal, Policy Tailwinds, and Renewed Chinese ADR Sentiment

**Julong Holding Limited Class A: Corporate Profile and Principal Business Operations** Julong Holding Limited was incorporated on August 7, 2023, under the laws of the Cayman Islands as an exempted company with limited liability. The Company conducts its principal business operations through its wholly-owned operating subsidiaries established in mainland China. Its core operating subsidiary, Julong Online (Beijing) Technology Development Co., Ltd., has been recognized as a National High-Tech Enterprise by the relevant PRC authorities. The subsidiary specializes in intelligent building system integration, information network system integration, fire linkage system integration, and comprehensive internet services. In addition, the Company undertakes large-scale engineering projects encompassing architectural decoration, curtain wall installation, electromechanical installation, and general contracting works.

**Julong Holding Limited Class A (JLHL) Surges 318% Amid Fundamental Strength and Capital Concentration** It is noteworthy that the sharp appreciation in Julong Holding Limited Class A (JLHL) shares can be attributed to several converging factors. The company's core subsidiary holds national high-tech enterprise designation, with business operations spanning intelligent building systems, information networks, and smart city infrastructure — sectors benefiting from favorable policy tailwinds, providing solid fundamental support. Additionally, with a market capitalization floor of approximately $79.1 million, JLHL represents a typical small-cap Chinese concept stock with limited float, making it highly susceptible to aggressive price movements driven by concentrated capital inflows. Furthermore, JLHL repeatedly topped after-hours gainers lists across multiple trading sessions — Monday, Tuesday, and Thursday — indicating sustained and systematic capital positioning. Combined with improving broader sentiment toward Chinese concept stocks, these multiple catalysts collectively propelled cumulative gains of **318%**.

FORTE BIOSCIENCES INC: Overnight gain 78.3%, Surges After FB102 Phase 1b Trial Delivers Positive Vitiligo Results

**FORTE BIOSCIENCES INC Advances Live Biotherapeutic Candidate FB-401 for Inflammatory Skin Conditions** Forte Biosciences, Inc. (the "Company") is a clinical-stage dermatology company focused on the development of FB-401, a proprietary live biotherapeutic product candidate targeting inflammatory skin diseases. The Company has successfully completed Phase 1/2a clinical trials evaluating FB-401 in adult patients and pediatric patients aged three years and older diagnosed with atopic dermatitis. Against a backdrop of robust market demand for safe and efficacious therapeutic options — particularly within the pediatric atopic dermatitis segment — the Company intends to advance FB-401 into Phase 2 clinical trials in the mid-2020s. This strategic development milestone underscores Forte Biosciences' commitment to addressing significant unmet medical needs in dermatological care and its continued execution of a disciplined clinical development strategy.

**FORTE BIOSCIENCES INC (FBRX) Surges 78.3% Following Positive Phase 1b Vitiligo Trial Results** Shares of FORTE BIOSCIENCES INC (FBRX) soared 78.3% in a single trading session after the company announced positive topline results from its double-blind, placebo-controlled Phase 1b study evaluating FB102 for the treatment of vitiligo. Clinical data demonstrated that FB102 achieved a mean 29.6% improvement from baseline in Facial Vitiligo Area Scoring Index (FVASI) at Week 24 (p=0.020), with the severe patient subgroup recording a notably stronger improvement of 43.2% (p=0.006). Importantly, 84% of participants showed continued improvement following treatment completion, with no observed deterioration. The safety profile remained favorable, with adverse events limited to mild-to-moderate severity. The multidimensional, above-expectation clinical outcomes substantially validated FORTE BIOSCIENCES INC's (FBRX) live biotherapeutic platform, significantly bolstering market confidence in the company's subsequent clinical advancement pipeline.

First Tracks Biotherapeutics Inc: Overnight gain 56.0%, Surges Amid Strong Buy Reaffirmation and Immunology Pipeline Optimism

**First Tracks Biotherapeutics, Inc. Incorporated as Wholly Owned Subsidiary of AnaptysBio, Inc.** First Tracks Biotherapeutics, Inc. was formally incorporated on October 17, 2025, pursuant to the laws of the State of Delaware, as a direct, wholly owned subsidiary of AnaptysBio, Inc. The newly established entity is positioned as a clinical-stage biopharmaceutical company focused on the research and development of novel immunotherapies targeting autoimmune and inflammatory diseases.

**First Tracks Biotherapeutics Inc (TRAX) Surges 56% Following Analyst Reaffirmation** Shares of First Tracks Biotherapeutics Inc (TRAX) posted a remarkable single-session gain of 56.0%, bringing year-to-date appreciation to 62.0% and lifting the company's market capitalization to approximately $1.131 billion. The rally was primarily catalyzed by HC Wainwright & Co. analyst Emily Bodnar reiterating a "Buy" rating on the stock while maintaining a $30 price target, delivering a strong institutional endorsement that directly bolstered market sentiment. As a clinical-stage biopharmaceutical company operating under AnaptysBio and focused on innovative therapies for autoimmune and inflammatory diseases, First Tracks Biotherapeutics Inc (TRAX) is strategically positioned within one of biotechnology's highest-conviction growth segments. The parent company's established immunology expertise and resource base further reinforce investor confidence, creating a confluence of fundamental and sentiment-driven factors underpinning the stock's robust performance.

Wrap Technologies, Inc.: Overnight gain 48.4%, Surges Amid Regulatory Clarity and Strategic Platform Launch Driving Valuation Re-rating

**Wrap Technologies, Inc. Delivers Innovative Law Enforcement Solutions with Expanding Market Reach** Wrap Technologies, Inc., a security technology company incorporated in the State of Delaware, was founded in March 2016 with a core focus on developing and delivering modernized policing solutions for law enforcement and security personnel. The Company launched its inaugural product, the BolaWrap 100 remote restraint device, in November 2017. Its primary addressable market encompasses approximately 701,000 full-time sworn law enforcement officers across the United States. To date, the Company has conducted product demonstrations with more than 60 agencies nationwide. Bolstered by extensive coverage across television and print media platforms, Wrap Technologies has generated significant inbound interest, attracting inquiries from hundreds of prospective customers both domestically and internationally.

**Wrap Technologies, Inc. (WRAP) Surges 48.4% on Dual Catalysts Driving Fundamental Revaluation** Shares of Wrap Technologies, Inc. (WRAP) posted a remarkable single-session gain of 48.4%, propelled by the simultaneous release of two significant catalysts that collectively triggered a fundamental reassessment of the company's valuation framework. First, the ATF issued Ruling 2026-2, formally classifying the BolaWrap® 150 as neither a "firearm" nor "any other weapon," designating it solely as a "restraint device" effective July 2, 2026. The ruling eliminates longstanding federal regulatory uncertainty that had materially impeded procurement advances across multiple markets. Second, the company concurrently unveiled WrapShield, an autonomous defense and public safety platform integrating advanced sensing, artificial intelligence, and command-and-control technologies. The launch signals a pivotal strategic transformation from a single non-lethal device manufacturer to a diversified platform-oriented enterprise. The convergence of these developments prompted market participants to substantially revise their valuation assumptions for WRAP.

NLIGHT, INC.: Overnight gain 27.3%, Surges Amid Rising Defense Demand and Industrial Laser Growth Expectations

**nLIGHT, Inc. Company Profile** Incorporated in the State of Washington in June 2000, nLIGHT, Inc. has established itself as a leading global provider of high-power semiconductor and fiber laser solutions. The Company maintains full vertical integration capabilities, encompassing the proprietary design, research and development, and manufacturing of core laser components across its entire product portfolio. As of fiscal year 2017, nLIGHT's diversified product offerings span three primary end markets: industrial manufacturing, micro-manufacturing, and aerospace and defense. The Company serves a broad and expanding global customer base of more than 300 clients worldwide, underscoring its strong market penetration and competitive positioning within the high-power laser industry.

**NLIGHT, INC. (LASR) Surges on Strong Industrial and Defense Demand Outlook** Shares of NLIGHT, INC. (LASR) have rallied sharply, driven by multiple converging catalysts. As a leading provider of high-power semiconductor and fiber lasers, the company leverages its proprietary vertically integrated capabilities to establish formidable technological barriers. Expanding demand across industrial applications — including cutting, welding, and additive manufacturing — continues to underpin robust growth expectations. Simultaneously, accelerating global defense expenditures have materially elevated demand for high-power lasers in directed-energy weapons and broader military applications, with growing defense order pipelines serving as a significant near-term catalyst. The company's diversified customer base of over 300 clients spanning three major global markets further reinforces investor confidence. NLIGHT, INC. (LASR) has now posted a cumulative year-to-date gain of 99.2%, complemented by an overnight single-session surge of 27.3%, reflecting sustained capital market re-rating of its dual-engine industrial and defense growth narrative.

MCDERMOTT INTERNATIONAL LTD: Overnight gain 17.7%, Surges Amid Major EPC Contract Wins and Strong Fundamental Recovery

**MCDERMOTT INTERNATIONAL LTD (MCDIF) Surges 17.7% Overnight, Year-to-Date Gains Reach 36.2%** Shares of MCDERMOTT INTERNATIONAL LTD (MCDIF), a globally recognized Engineering, Procurement, and Construction (EPC) contractor, posted a sharp overnight gain of 17.7%, bringing year-to-date cumulative returns to 36.2%. The near-term spike is widely attributed to the potential announcement of a significant EPC contract award or material business development, which has notably bolstered market sentiment. Examining the broader year-to-date trajectory, the 36.2% cumulative appreciation reflects growing investor confidence in the company's ongoing fundamental recovery and the tangible progress of its business restructuring initiatives. Additionally, a resurgent demand for energy infrastructure construction continues to underpin a favorable order outlook for MCDERMOTT INTERNATIONAL LTD (MCDIF), providing sustained momentum for capital inflows into the stock.

Fervo Energy Company Class A: Overnight gain 16.0%, Surges Amid Cape Station Progress, PPA Agreements, and Geothermal Sector Momentum

**Fervo Energy Company Class A — Corporate Profile & Project Update** Fervo Energy Company was incorporated in the State of Delaware in May 2017. The company specializes in the development of Enhanced Geothermal Systems (EGS), leveraging horizontal drilling and multi-stage hydraulic fracturing technologies to convert geothermal resources into utility-scale clean electricity. The company's commercial pilot project, **Red**, has been delivering clean power to the grid on a continuous basis since 2023, generating commercial revenues in the process. Building on this operational track record, Fervo is currently advancing the construction of **Cape Station**, a 500-megawatt (MW) greenfield development project, with first power delivery targeted for completion before year-end 2026. In support of the project's offtake framework, the company has executed binding Power Purchase Agreements (PPAs) with a portfolio of investment-grade counterparties, including utility and corporate energy buyers such as **Southern California Edison** and **Shell**, underscoring strong institutional demand for its clean energy output.

**Fervo Energy Company Class A (FRVO) Surges 16.0% on Project Milestones and Sector Sentiment Recovery** Shares of Fervo Energy Company Class A (FRVO) posted a notable single-day gain of 16.0%, driven by a confluence of catalysts. As a pioneer in Enhanced Geothermal Systems (EGS), the company's proprietary application of horizontal drilling and hydraulic fracturing to geothermal development continues to attract growing sector interest. The approaching construction milestone for Cape Station — a 500MW utility-scale project slated for initial power delivery by late 2026 — is prompting early institutional positioning. Additionally, binding Power Purchase Agreements (PPAs) executed with investment-grade offtakers including Southern California Edison and Shell have bolstered cash flow visibility. The commercial pilot project Red has been delivering clean power to the grid and generating tangible revenue since 2023, validating operational viability. With a modest year-to-date gain of just 1.3% prior to this move, the rally reflects both project-driven catalysts and a broader sentiment recovery.

BridgeBio Pharma: Overnight gain 15.1%, Surges Amid Rival Trial Failure, FDA Approval, and Major Institutional Backing

**BridgeBio Pharma, Inc.** was incorporated in the State of Delaware on May 17, 2019, and operates as a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of innovative therapeutics targeting genetic diseases and oncology, with a particular emphasis on conditions driven by well-defined genetic alterations. Through its pipeline of novel drug candidates, BridgeBio Pharma seeks to address significant unmet medical needs in patient populations with clearly characterized genetic underpinnings.

**BridgeBio Pharma(BBIO) Surges 15.1% on Multiple Catalysts** Shares of BridgeBio Pharma(BBIO) soared 15.1% in a single session, driven by a confluence of positive developments. A key competitive tailwind emerged as AstraZeneca and Ionis Pharmaceuticals announced the failure of their Phase III CARDIO-TTRansform trial, with RNA-targeting silencer Wainua failing to meet its primary endpoint — materially improving BridgeBio Pharma(BBIO)'s competitive positioning in the ATTR-CM space. Simultaneously, the company's ATTR-CM therapy Attruby continues to advance commercially following FDA approval. JPMorgan initiated coverage with an **Overweight** rating and a $27 price target, signaling institutional confidence in the company's trajectory. Further bolstering sentiment, KKR and Sixth Street Partners committed $1 billion in financing to accelerate the launch of BridgeBio Pharma(BBIO)'s innovative genetic disease pipeline. The convergence of these catalysts — competitive landscape improvement, commercial momentum, analyst endorsement, and substantial capital infusion — collectively propelled the stock's sharp single-day rally.

10x Genomics: Overnight gain 15.0%, Surges After Citi Raises Price Target, Boosting Market Confidence

**Torex Gold Resources Inc.** is a mid-tier gold and precious metals producer with a focused operational mandate centered on the exploration and development of its wholly owned Morelos Gold Property in Mexico. The asset encompasses approximately 29,000 hectares situated within the highly prospective Guerrero Gold Belt, approximately 180 kilometers southwest of Mexico City. The Company's core asset portfolio comprises the producing El Limon-Guajes open-pit gold mining complex, located north of the Balsas River, alongside the Media Luna Project, which is currently advancing through the late-stage exploration phase.

**10x Genomics(TXG) Surges 15% as Citi Raises Price Target by 88%** Shares of 10x Genomics(TXG) posted a robust single-session gain of 15%, driven by two converging catalysts. Notably, Citibank reaffirmed its "Neutral" rating on the stock while substantially raising its price target from $24 to $45, representing a near 88% upward revision. The aggressive target adjustment significantly bolstered market confidence, serving as the primary catalyst behind the sharp intraday advance. Concurrently, 10x Genomics(TXG) has now accumulated a remarkable year-to-date gain of approximately 164.3%, with the stock's sustained upward momentum continuing to reinforce positive market sentiment. The combination of Citi's bullish price target revision and the stock's exceptional year-to-date performance has attracted momentum-driven investors to establish new positions, with both factors resonating in tandem to propel the latest leg of this significant upside move.

Larimar Therapeutics, Inc.: Overnight gain 14.4%, Surges Driven by CPP Technology Platform Strength and Rare Disease Market Confidence

**Larimar Therapeutics, Inc.** was incorporated under the laws of the State of Delaware on November 22, 2005, and operates as a clinical-stage biopharmaceutical company. The Company is focused on leveraging its proprietary novel cell-penetrating peptide (CPP) technology platform to advance the development of innovative therapeutic solutions for patients suffering from rare and complex diseases.

**Larimar Therapeutics, Inc. (LRMR) Surges 14.4% Overnight Amid Renewed Market Confidence** Shares of Larimar Therapeutics, Inc. (LRMR), a clinical-stage biopharmaceutical company focused on complex rare diseases, surged 14.4% overnight, bringing year-to-date gains to 8.4%. The rally was driven by multiple converging factors. The company's proprietary cell-penetrating peptide (CPP) technology platform continues to demonstrate differentiated advantages in rare disease drug delivery, prompting ongoing market reassessment of its commercialization potential. Additionally, the rare disease sector inherently benefits from favorable structural tailwinds, including premium drug pricing power, orphan drug designation incentives, and limited competitive pressure — dynamics that collectively support elevated valuation premiums. The sustained positive year-to-date performance further underscores the market's constructive view of Larimar Therapeutics, Inc.'s (LRMR) fundamentals, with the latest price appreciation representing a concentrated release of accumulated investor confidence in the company's long-term prospects.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.